BRENTUXIMAB

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2018
0520122018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Patients with common variable immunodeficiency (CVID) have an increased risk of developing lymphoproliferative diseases… (More)
  • figure 1
  • figure 2
Is this relevant?
2016
2016
Monoclonal antibody therapy is a new innovation in cancer therapy. Binding of monoclonal antibodies to tumor cells facilitates… (More)
Is this relevant?
2016
2016
Acute pulmonary toxicity associated with brentuximab appears to be a rare but serious adverse effect that can be potentially… (More)
Is this relevant?
2015
2015
IMPORTANCE The prognosis of advanced cutaneous T-cell lymphoma (CTCL), including Sézary syndrome and mycosis fungoides (MF), is… (More)
Is this relevant?
2015
2015
BACKGROUND The optimal treatment of patients with heavily pretreated Hodgkin's lymphoma is controversial. Brentuximab vedotin is… (More)
Is this relevant?
2015
2015
Among haematological malignancies, Hodgkin’s lymphoma (HL) remains a disease with a high cure rate and overall survival rate of… (More)
  • table 1
  • table 2
Is this relevant?
2014
2014
BACKGROUND Brentuximab vedotin (BV) is an anti-CD30 monoclonal antibody-drug conjugate that was approved in 2011 for the… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Therapeutic monoclonal antibodies (mAbs) are currently being approved for marketing in Europe and the United States, as well as… (More)
Is this relevant?
2012
2012
A 38-year-old woman was diagnosed with cutaneous anaplastic T-cell lymphoma that proved refractory to methotrexate, bexarotene… (More)
Is this relevant?
Review
2012
Review
2012
INTRODUCTION Brentuximab vedotin is an antibody-drug conjugate which consists of the anti-CD30 monoclonal antibody cAC10… (More)
Is this relevant?